{
    "ticker": "GLMD",
    "name": "Galmed Pharmaceuticals Ltd.",
    "description": "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH) and other related metabolic disorders. Founded in 2000 and headquartered in Tel Aviv, Israel, Galmed is dedicated to addressing unmet medical needs through the advancement of novel drug candidates. The company's lead product candidate, Aramchol, is a first-in-class drug that is currently in clinical trials aimed at treating liver diseases characterized by fat accumulation and inflammation. Galmed\u2019s approach leverages a proprietary platform to discover and develop therapies that target metabolic and fibrotic processes in the liver. By focusing on diseases that affect millions globally, Galmed seeks to improve the lives of patients while also delivering value to its shareholders. The company is driven by a commitment to scientific excellence and innovation, positioning itself as a leader in the burgeoning field of liver disease therapeutics.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Tel Aviv, Israel",
    "founded": "2000",
    "website": "https://www.galmedpharmaceuticals.com",
    "ceo": "Alan M. Cohen",
    "social_media": {
        "twitter": "https://twitter.com/GalmedPharma",
        "linkedin": "https://www.linkedin.com/company/galmed-pharmaceuticals-ltd/"
    },
    "investor_relations": "https://www.galmedpharmaceuticals.com/investors",
    "key_executives": [
        {
            "name": "Alan M. Cohen",
            "position": "CEO"
        },
        {
            "name": "Yoram P. Cohen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Aramchol"
            ]
        }
    ],
    "seo": {
        "meta_title": "Galmed Pharmaceuticals Ltd. | Innovating Liver Disease Therapies",
        "meta_description": "Explore Galmed Pharmaceuticals Ltd., a leader in biopharmaceutical innovation focusing on liver diseases such as NASH. Learn about their groundbreaking therapies and commitment to patient care.",
        "keywords": [
            "Galmed Pharmaceuticals",
            "Liver Disease",
            "NASH",
            "Biopharmaceuticals",
            "Aramchol"
        ]
    },
    "faq": [
        {
            "question": "What is Galmed Pharmaceuticals known for?",
            "answer": "Galmed Pharmaceuticals is known for developing therapies for liver diseases, especially non-alcoholic steatohepatitis (NASH)."
        },
        {
            "question": "Who is the CEO of Galmed Pharmaceuticals?",
            "answer": "Alan M. Cohen is the CEO of Galmed Pharmaceuticals Ltd."
        },
        {
            "question": "Where is Galmed Pharmaceuticals headquartered?",
            "answer": "Galmed Pharmaceuticals is headquartered in Tel Aviv, Israel."
        },
        {
            "question": "What is Galmed's lead product candidate?",
            "answer": "Galmed's lead product candidate is Aramchol, aimed at treating liver diseases."
        },
        {
            "question": "When was Galmed Pharmaceuticals founded?",
            "answer": "Galmed Pharmaceuticals was founded in 2000."
        }
    ],
    "competitors": [
        "ALNY",
        "GILD",
        "AMGN",
        "PHAS"
    ],
    "related_stocks": [
        "JNJ",
        "MRNA",
        "PFE",
        "BMY"
    ]
}